China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron BA.5 mRNA vaccine, LVRNA012, based on a trial conducted on the China mainland. The study, which aimed to assess the protective efficacy, safety, and immunogenicity of LVRNA012 as a booster shot in individuals aged 18 and above, has completed an interim analysis of key data and obtained the main results.
Interim Analysis Results and Vaccine Efficacy
The interim analysis showed that most of the COVID-19 cases collected 7 days after vaccination exhibited mild symptoms, with very few cases presenting medium symptoms. The protection rate achieved by the vaccine was 73.16% (95% CI 54.24% – 85.00%). These results indicate the potential of LVRNA012 in providing protection against the Omicron BA.5 variant and contribute to the ongoing efforts in combating the pandemic.
Implications for Public Health and Vaccine Strategy
The positive interim results from the trial are significant for public health strategies, particularly as they relate to the development of vaccines that can effectively address emerging variants of concern. The vaccine’s ability to induce a robust immune response and provide protection against mild to moderate symptoms is a crucial factor in reducing the severity of COVID-19 cases and the strain on healthcare systems.-Fineline Info & Tech
